pharmaphorum

APRIL 7, 2021

Genmab’s success has been founded on Darzalex (daratumumab), the blockbuster multiple myeloma drug that it developed in partnership with Johnson & Johnson’s Janssen unit. With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies.

Antibody 65

Antibody Life Science Development Regulation 65

The Pharma Data

NOVEMBER 1, 2020

This clinical trial will be coordinated by the team at the INTRIALS, a leading, full-service Latin America Clinical Research Organization (CRO), based in Sao Paulo City, Brazil. The clinical data from this trial is expected to available by the end of this year. Brazil has reported almost 5.5M About Tiziana Life Sciences.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Life Science 52

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

The Pharma Data

DECEMBER 14, 2020

NASDAQ: TGTX), a biopharmaceutical company developing medicines for patients with B-cell mediated diseases (“the Company”), today announced the pricing of an underwritten public offering of 6,320,000 shares of common stock at a public offering price of $43.50 NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) — TG Therapeutics, Inc.

Clinical Trials 40

Clinical Trials Clinical Trials Clinical Development Antibody 40

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

The Pharma Data

SEPTEMBER 28, 2021

“Triple-negative carcinoma grows and spreads faster than other sorts of carcinoma and consequently features a worse prognosis,” said Dr. Vicki Goodman, vice chairman , clinical research, Merck Research Laboratories. Merck has the industry’s largest immuno-oncology clinical research program.

Hormones 52

Hormones Medicine Clinical Research Research 52

The Pharma Data

DECEMBER 17, 2020

Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

Development 52

Development Gene Therapy Engineer Life Science 52

The Pharma Data

MARCH 23, 2023

Head of Global R&D ad interim and Chief Medical Officer at Sanofi “Change cannot come quick enough for people living with uncontrolled COPD but , unfortunately , many investigational treatments have failed to demonstrate significant clinical outcomes leaving these vulnerable patients with limited treatment options. In the U.S.

Trials 40

Trials Antibody Genetics Development 40

The Pharma Data

NOVEMBER 10, 2020

First Ever Study with take-home capsules of Foralumab , a Fully Human Anti-CD3 Monoclonal Antibody. Phase1b/2 clinical study to be conducted in the United States and several European countries. P otential to be a safer and effective alternative to the intravenous immunotherapies currently used for Crohn’s Disease.

Life Science 40

Life Science Clinical Trials Clinical Trials Trials 40

The Pharma Data

APRIL 8, 2021

“Since its first approval in renal cell carcinoma nearly two years ago, KEYTRUDA has become an important first-line treatment option in combination with axitinib for patients with advanced renal cell carcinoma,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

Trials 52

Trials Clinical Development Antibody Clinical Research 52

Pfizer

FEBRUARY 16, 2023

GCP is the international ethical and scientific quality standard for clinical trials that all clinical researchers need to follow. 2-4 About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development. 5,6 The program was granted Fast Track designation by the U.S. FDA in July 2017.

Clinical Trials 76

Clinical Trials Clinical Trials Vaccination Vaccine 76

Pharmaceutical Technology

AUGUST 16, 2022

Gilead Sciences has entered an agreement with Everest Medicines to acquire complete rights to develop and market Trodelvy (sacituzumab govitecan) in Greater China, Singapore, South Korea, Philippines, Vietnam, Thailand, Indonesia, Mongolia and Malaysia. Gilead will also have a chance to hire Everest staff working on the Trodelvy programme.

Marketing 255

Marketing Medicine Clinical Development Development 255

The Pharma Data

JANUARY 14, 2021

Associate Professor of Medicine at UCLA, Co-director of the Gastrointestinal Oncology Program and Director of Early Phase Clinical Research at the Jonsson Comprehensive Cancer Center. The fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) pathway is implicated in the development and growth of cancer cells.

Trials 52

Trials HR Containment Development 52

The Pharma Data

NOVEMBER 5, 2020

acousia Therapeutics – Jonas Dyhrfjeld-Johnsen joined Germany-based Acousia in the new role of chief development officer. Horizon Therapeutics – Karin Rosén joined Ireland-based Horizon Therapeutics as executive vice president, research and development and chief scientific officer. medical affairs at GlaxoSmithKline.

Genome 40

Genome Genomics Medicine Life Science 40

The Pharma Data

JUNE 25, 2021

Merck is continuing to study KEYTRUDA, in combination or as monotherapy, as well as other investigational products across multiple settings and stages of RCC including adjuvant and advanced or metastatic disease through our broad clinical development program, which includes over 20 clinical studies and more than 4,000 patients.

HR 52

HR Trials Clinical Research Research 52

XTalks

DECEMBER 4, 2020

Since CKD is a broad diagnosis that can have a variety of underlying causes, a beneficial focus of current research strategies has been to identify biomarkers and develop diagnostics that can help stratify patients into clinically relevant categories and help guide their management. Five Stages of CKD.

Trials 52

Trials Clinical Trials Clinical Trials Antibody 52

Drug Discovery World

AUGUST 8, 2022

DDW Editor Reece Armstrong speaks to Stephanie Seremetis, Chief Medical Officer, Rare Blood Disorders at Novo Nordisk to get her response to the company’s latest study results for its Mim8 antibody. We look forward to moving into phase 3 clinical development, which is due to commence in Q4 2022.

Antibody 52

Antibody Clinical Trials Clinical Trials Clinical Development 52

The Pharma Data

SEPTEMBER 1, 2020

study investigator and Professor of Clinical Neurology, University of California San Francisco (UCSF) Weill Institute for Neurosciences and clinical research director, UCSF MS Center. head of Immunology and Fibrosis Development, Bristol Myers Squibb. Presentation Topic: Clinical Trials. Author: Selmaj.

Trials 52

Trials Clinical Trials Clinical Trials Vaccination 52

The Pharma Data

OCTOBER 27, 2020

Molecular Partners, a global leader in the development of DARPin® therapeutics, will be responsible for the conduct of phase 1 & 2 trials that may lead to emergency use approval; Novartis will be responsible for further development, manufacturing, distribution and commercialization.

Development 52

Development Protein Manufacturing Medicine 52

Drug Discovery World

MAY 30, 2023

From antibody-drug conjugates and RNA, to CRISPR and CAR-T therapy, DDW asked the drug discovery industry what the most important development in oncology over the last five years has been. We expect this field to grow significantly in the coming years as these and other earlier stage assets are developed. Here are their answers.

Research 52

Research Drugs Protein RNA 52

The Pharma Data

JULY 15, 2021

“These highly anticipated event-free survival results in this TNBC population build upon earlier findings from the KEYNOTE-522 trial and further support the potential use of KEYTRUDA in these patients,” said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories.

HR 52

HR Trials Clinical Development Clinical Research 52

Drug Discovery World

OCTOBER 7, 2022

RA: How can the integration of industry and academia help streamline drug development? . HR : We want to streamline the drug discovery and development process for our industry partners. RA : In terms of the UK landscape, what are some of the biggest barriers researchers face for bringing an oncology drug to market? .

HR 52

HR Research Drugs Development 52

The Pharma Data

JUNE 26, 2021

Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen Research & Development, LLC. About EXPLORER The EXPLORER clinical research program is unmatched by any oral anticoagulant in the Factor Xa inhibitor class in its size, scope and ambition. Tell your doctor if you take any of these medicines.

Doctors 52

Doctors Doctor Medicine Clinical Trials 52

The Pharma Data

APRIL 4, 2023

First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Merck has the industry’s largest immuno-oncology clinical research program.

FDA Approval 40

FDA Approval Containment Hormones Dermatology 40

The Pharma Data

AUGUST 10, 2021

“The FDA’s acceptance of our application adds to our momentum of advancing new treatment options to address the most challenging cancers facing women,” said Dr. Scot Ebbinghaus, vice president, clinical research, Merck Research Laboratories. Merck has the industry’s largest immuno-oncology clinical research program.

Trials 52

Trials Clinical Research Licensing Licensing 52

The Pharma Data

MARCH 23, 2021

“There have been few advances in improving survival outcomes in the first-line treatment setting for esophageal cancer over the last three decades,” said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. “We

HR 52

HR FDA Approval Containment Genome 52

The Pharma Data

OCTOBER 14, 2020

Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML. VBL is currently advancing its lead anti-MOSPD2 candidate through IND-enabling studies.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52

XTalks

SEPTEMBER 14, 2020

And in truth, the companies the White House picked were pretty savvy as several are current front-runners in the race to develop a vaccine. The company is also in collaboration with Ridgeback Biotherapeutics to develop a novel oral antiviral treatment for COVID-19. In older adults, the same vaccine elicited neutralizing antibodies 1.6

Vaccination 92

Vaccination Vaccine Antibody Life Science 92